January 06, 2011
Korea University reports research in liver disease
By
NewsRx.com
"The purpose of this study was to describe magnetic resonance (MR) findings of focal eosinophilic liver disease using gadoxetic acid (Gd-EOB-DTPA). Nineteen patients (M:F:5; age range, 26-66 years; mean age, 50 years) with 35 focal eosinophilic liver lesions were included after reviewing the medical records of 482 patients who underwent Gd-EOB-DTPA-enhanced MR imaging (MRI) on a 3.0-T unit between April 2008 and June 2009," investigators in Seoul, South Korea report (see also Liver Disease).
"The diagnosis of focal eosinophilic liver disease was established by means of percutaneous liver biopsy or surgery and consistent clinical findings. Two radiologists retrospectively reviewed MR images with consensus. Margin, shape and distribution of the lesions were analyzed. We also evaluated signal intensity of focal hepatic lesions on T-1- and T-2-weighted images and patterns of enhancement in dynamic contrast study. The mean diameter of the lesions was 1.7 cm (range, 0.7-6.1 cm). Most of the focal eosinophilic liver lesions [n1/35 (88.6%)] had poorly defined margins. They were usually isointense or slightly hypointense [n4/35 (97.2%)] on T-1-weighted images and hyperintense [n2/35 (91.4%)] on T-2-weighted images. Dynamic study showed enhancement (rim or homogeneous) on the arterial phase [n!/35 (60%)] and hypointensity on the late venous phase [n1/35 (88.6%)]. All the lesions were hypointense on the hepatobiliary phase images. Focal eosinophilic liver lesions tend to be hyperintense on the arterial phase and hypointense on the late venous phase during dynamic study of Gd-EOB-DTPA-enhanced MRI," wrote J. Lee and colleagues, Korea University.
The researchers concluded: "Although these findings mimic other focal hepatic lesions, poorly defined margins of the lesions and peripheral eosinophilia might help distinguish focal eosinophilic liver disease from other hepatic lesions."
Lee and colleagues published their study in Magnetic Resonance Imaging (MR findings of focal eosinophilic liver disease using gadoxetic acid. Magnetic Resonance Imaging, 2010;28(9):1327-1334).
For additional information, contact J. Lee, Korea University, College Medical, Guro Hospital, Dept. of Radiol, Seoul 152703, South Korea.
The publisher of the journal Magnetic Resonance Imaging can be contacted at: Elsevier Science Inc., 360 Park Avenue South, New York, NY 10010-1710, USA.
Keywords: City:Seoul, Country:South Korea, Blood Cells, Digestive System Diseases, Eosinophils, Granulocytes, Hemic and Immune Systems, Human, Immunology, Liver Diseases, Magnetic Resonance
This article was prepared by Hematology Week editors from staff and other reports. Copyright 2011, Hematology Week via NewsRx.com.
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .
This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
- Home
- Newly Diagnosed With Hep C? Or Considering Treatment?
- All FDA Approved Drugs To Treat Hepatitis C
- Hepatitis C Genotypes and Treatment
- Mavyret (glecaprevir/pibrentasvir)
- Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Zepatier(Elbasvir/Grazoprevir)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- HCV Liver Fibrosis
- FibroScan® Understanding The Results
- HCV Cirrhosis
- Staging Cirrhosis
- HCV Liver Cancer
- Risk Of Developing Liver Cancer After HCV Treatment
- Treating Elderly HCV Patients
- Fatty Liver Disease: NAFLD/NASH
- Current research articles on ailments that may be related to HCV
- Is There A Natural Way To Improve Liver Fibrosis?
- Can Food Or Herbs Interact With Conventional Medical Treatments?
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment